News >

Frontline Approaches Fine-Tuned in Newly Diagnosed Ovarian Cancer

Caroline Seymour
Published: Friday, Apr 05, 2019

Paul Sabbatini, MD

Paul Sabbatini, MD
The decision of whether or not to use frontline bevacizumab (Avastin), intraperitoneal (IP) therapy, and administer chemotherapy as a weekly dose-dense regimen or on a 3-week dosing schedule in patients with newly diagnosed ovarian cancer has been clouded by a series of conflicting clinical trials.

State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma, Sabbatini clarified where the field stands regarding the use of these modalities in the frontline setting of newly diagnosed ovarian cancer.

OncLive: How has the frontline setting of ovarian cancer evolved over the years?

Sabbatini: We've looked at several different modalities, including IP therapy, the addition of anti-vascular therapies, as well as changing the dosing schedule of frontline therapy. Based on several randomized studies, we've come to a place where we've decided that there doesn't appear to be an advantage with IP chemotherapy. There was a robust advantage to weekly chemotherapy in the Japanese GOG3016 study, but it appeared to be less so in the subsequent GOG262 study.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication